© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#lung cancer

lungs
Tecentriq Plus Chemotherapy Slows Progression of Advanced Lung Cancer
Trained Dogs Can Identify Lung Cancer, Study Shows
Lung Cancer 101
November 15 is the annual Great American Smokeout.

There Is Hope for a Future With Less Lung Cancer

This month, we raise awareness about what lung cancer is, how to lower your risk, and how important screening is for those at high risk.

Keytruda

An X-ray of non-small cell lung cancer in a 54-year-old woman

Trial Results Highlight Changing Lung Cancer Treatment Landscape

In non-small cell lung cancer, new drugs like brigatinib and crizotinib can dramatically shrink tumors with an ALK alteration.

FDA Approves Lorbrena for ALK-Positive Lung Cancer

Lorlatinib shrinks tumors in half of patients previously treated with older ALK inhibitors.

Lorbrena

LUNG FORCE Expo - New York

Program designed for patients, caregivers and healthcare providers to learn more about latest trends
Low-dose CT scanner

November is Lung Cancer Awareness Month. Have you ever received screening to detect lung cancer early?

The AI-driven computer program analyzes tissue by creating a map of thousands of tiles. The map on the right shows squamous cell carcinoma (red), lung squamous cell carcinoma (blue), and normal lung tissue (gray).

Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations

The program proved as accurate as experienced pathologists at diagnosing adenocarcinomas and squamous cell carcinomas.

Keytruda Plus Chemotherapy Approved for Metastatic Squamous Lung Cancer

Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.

FDA Approves Keytruda Plus Chemotherapy for First Treatment of Metastatic Lung Cancer

Median overall survival was 15.9 for the combination versus 11.3 months for chemotherapy alone.
This image shows how lung cancer cells invade surrounding tissues and start to metastasize. These lung cancer cells have a mutation of a gene called LKB1 (in green) that promotes invasion.

Immunotherapy Drug Finally Improves Survival for Small Cell Lung Cancer

Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
Christopher Li, MD, PhD (left), Jason Bielas, PhD, and colleagues are teaming up on a $2.4 million project that seeks to better understand the link between personal mutation rate and individual cancer risk.

Bringing Personalized Oncology to Cancer Prediction — and Prevention

Cancer geneticists, epidemiologists and oncologists team up to use mutation rate to predict individual cancer risk.
Joaquin Espinosa, PhD

CRISPR Screen Reveals New Targets in Squamous Cell Carcinomas

“The challenge now is to exploit this knowledge for therapeutics,” says researcher Joaquin Espinosa, PhD.

Imfinzi Improves Survival for People With Advanced Lung Cancer

Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.

FDA Approves Vizimpro for Metastatic Non-Small-Cell Lung Cancer

Targeted therapy approved first-line treatment of cancer with specific genetic mutations.
D. Ross Camidge, MD, PhD

ALK Inhibitor Alunbrig Slows Progression of Advanced Lung Cancer

Targeted therapy reduced risk of disease progression or death by about 50 percent.
Advertisement